India Pharma's China+1 Moment: Real Gains in CDMOs, Formulations; API Self-Sufficiency Remains a Decade Away

Post-COVID supply-chain anxiety and the BIOSECURE Act are steering Western pharma toward Indian CDMOs and finished-dose makers, but China's 20-40% API cost edge and India's own 65-70% KSM import dependency cap near-term substitution.

bt-corporate · 6/29/2026, 4:46:39 AM · Ask about this →